Michael Chisamore

Company: Merck & Co

Job title: Executive Director, Clinical Development

Seminars:

Panel Discussion: Shaping the Future of Cancer Immunotherapy Combinations with Strategic Partnerships & Collaborations to Bring Precise & Effective Treatments to Patients 9:30 am

• How to successfully identify complimentary immuno-oncology platforms such as adoptive cells, Bispecific T cell engagers, oncolytic viruses and beyond to discover and develop novel and life-saving cancer immunotherapy combinations? • How to overcome challenges such as stakeholder management, funding and resource to provide a wide range of cancer patients with improved access to treatment…Read more

day: Day One

Cancer Immunotherapy Combined with ADCs: Exploiting Novel & Rational Combinations 11:00 am

• Combining cancer immunotherapy with ADCs: Independent action verses synergy • Cancer immunotherapy combined with ADCs: Combinations based on efficacy response • Does adding in chemotherapy provide additional benefit to cancer immunotherapy combined with ADC’s?Read more

day: Day One